首页> 美国卫生研究院文献>Thoracic Cancer >SHR‐1316 an anti‐PD‐L1 antibody plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre phase 2 study

【2h】

SHR‐1316 an anti‐PD‐L1 antibody plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre phase 2 study

机译：SHR-1316抗PD-L1抗体加上化疗作为先进食道鳞状细胞癌的第一线治疗：多期第2期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

This multicentre, open‐label study evaluated the efficacy and safety of antiprogrammed death ligand 1 antibody SHR‐1316 plus liposomal irinotecan and 5‐fluorouracil as the first‐line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC).

机译：这种多长期开放标签研究评估了抗腹部死亡配体1抗体SHR-1316加上脂质体氨基丙烷和5-氟尿嘧啶的疗效和安全性作为先进食管鳞状细胞癌（ESCC）的患者的一线治疗。

著录项

期刊名称 Thoracic Cancer
作者
Lan Mu; Yan Song; Kuaile Zhao; Ying Liu; Qingxia Fan; Xi Wang; Qun Li; Xiaopeng Wang; Jing Huang;
展开▼
作者单位

展开▼
年(卷),期 2021(12),9
年度 2021
页码 1373–1381
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

机译：抗PD-L1抗体;化疗;食管鳞状细胞癌;脂质体IRINOTECAN;

相似文献

外文文献
中文文献
专利

1. SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study [J] . Lan Mu, Yan Song, Kuaile Zhao, Thoracic cancer. . 2021,第9期

机译：SHR-1316，抗PD-L1抗体，加上化疗作为先进食管鳞状细胞癌的一线治疗：多期，第2期研究
2. Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma [J] . Bo Zhang, Xi Wang, Qun Li, 中国癌症研究（英文版） . 2019,第006期

机译：接受抗PD-1抗体后基于伊立替康的化疗对晚期食管鳞状细胞癌的疗效
3. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study [J] . The lancet oncology . 2020,第6期

机译：Camrelizumab与调查员选择化疗作为先进或转移性食管鳞状细胞癌的二线治疗（护送）：多期，随机，开放标签，第3阶段研究
4. Personalized and targeted therapy of esophageal squamous cell carcinoma: an update [C] . Yongjing Liu, Zhaohui Xiong, Andrea Beasley, World Organization for Specialized Studies on Diseases of the Esophagus World Congress . 2017

机译：食管鳞状细胞癌的个性化和靶向治疗：更新
5. Identification of Novel Candidate Tumor Suppressor Genes at 11q and 15q for Esophageal Squamous Cell Carcinoma and Nasopharyngeal Carcinoma via Integrative Cancer Epigenetics and Genomics. [D] . Li, Jisheng. 2010

机译：通过综合癌症表观遗传学和基因组学鉴定食管鳞状细胞癌和鼻咽癌的11q和15q新型候选肿瘤抑制基因。
6. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR‐1210) a novel anti‐PD‐1 antibody [O] . Xi Wang, Bo Zhang, Xuelian Chen, 2019

机译：乳酸抗脱氢酶和基线标志物与接受新型抗PD-1抗体卡雷珠单抗（SHR-1210）治疗的晚期食道鳞状细胞癌患者的临床结局相关
7. Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma [O] . Bo Zhang, Xi Wang, Qun Li, 2019

机译：伊替康的化疗在晚期食管鳞状细胞癌患者中暴露于抗PD-1抗体后的疗效

SHR‐1316 an anti‐PD‐L1 antibody plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre phase 2 study

摘要

著录项

相似文献

相关主题

期刊订阅